ÂÜÀòÂÒÂ×

Katja Wendicke Lophaven is an experienced senior medical professional with a robust background in pharmaceutical sciences and extensive expertise in clinical research and medical affairs. Since September 2014, Katja has held various senior roles at LEO Pharma, currently serving as Senior Medical Director and previously as Principal Medical Adviser and Principal Professional in Pharmacoepidemiology. Prior to this, Katja worked at Novo Nordisk as a Regulatory Professional in Clinical and at Takeda Pharmaceuticals as an International Medical Advisor, focusing on areas such as haemostasis and pain. Katja's earlier career at LEO Pharma included roles as Medical Advisor and International Trial Manager, primarily in dermatology, overseeing clinical development and trials. The academic foundation was established with a Master of Science in Pharmaceutical Sciences from Danmarks Farmaceutiske Universitet, obtained from 1992 to 1999.